Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Acerta Pharma BV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)